This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will host an analyst and institutional investor meeting on Thursday, October 4, 2012, from 5:00 to 6:30 PM Eastern Time in New York City. The event will include an overview of vosaroxin and the VALOR trial, a pivotal Phase 3, randomized, controlled, double-blind, multinational clinical trial in first relapsed or refractory acute myeloid leukemia (AML), as well as the Less Intensive 1 (LI-1) Study being conducted by the United Kingdom's National Cancer Research Institute (NCRI) Haematological Oncology Study Group.
The event will be moderated by Daniel Swisher, Chief Executive Officer of Sunesis, and will include presentations by, and an in depth panel discussion with, key opinion leaders in AML, including VALOR principal investigators. Presentations will be followed by a question and answer session.
The panel will include:
Alan K. Burnett, MD, Professor of Medicine, Head of Haematology, Department of Medical Genetics, Haematology and Pathology at Cardiff University School of Medicine;
Eric Feldman, MD, Chair of the VALOR Steering Committee, Professor of Medicine and Director of the Leukemia Program and Hematological Malignancies at Weill Cornell Medical College; and
Farhad Ravandi, MD, a principal investigator of VALOR, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
A live webcast of the event will be available on the Sunesis website at
http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website following the event.
VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial in patients with first relapsed or refractory AML. The trial's target enrollment is 675 patients at more than 110 leading sites in the U.S., Canada, Europe, Australia and New Zealand. The VALOR trial is currently enrolling patients, who are randomized one to one to receive either vosaroxin on days one and four in combination with cytarabine daily for five days, or placebo in combination with cytarabine. The trial's primary endpoint is overall survival. For more information on the VALOR trial, please visit
Vosaroxin is a first-in-class anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Both the U.S. Food and Drug Administration (FDA) and European Commission have granted orphan drug designation to vosaroxin for the treatment of acute myeloid leukemia. Additionally, vosaroxin has been granted fast track designation by the FDA for the potential treatment of relapsed or refractory acute myeloid leukemia in combination with cytarabine.